CARGO Therapeutics (CRGX) to Release Quarterly Earnings on Thursday

CARGO Therapeutics (NASDAQ:CRGX) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

CARGO Therapeutics Price Performance

Shares of NASDAQ CRGX opened at $4.15 on Thursday. CARGO Therapeutics has a fifty-two week low of $3.00 and a fifty-two week high of $33.84. The stock has a market capitalization of $191.02 million, a PE ratio of -0.97 and a beta of 1.63. The business has a fifty day moving average price of $7.57 and a two-hundred day moving average price of $14.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CRGX shares. William Blair cut CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, January 30th. HC Wainwright cut CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. Piper Sandler cut CARGO Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $34.00 to $4.00 in a report on Thursday, January 30th. Chardan Capital cut CARGO Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 30th. Finally, Jefferies Financial Group cut CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $32.00 to $3.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $15.00.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.